The report was released by TranspariMED (UK) along with BUKO Pharma-Kampagne (Germany), Test Aankoop (Belgium) and Health Action International (Netherlands).

The international coalition of health integrity groups demanded that European universities must make the results of all their clinical trials public to safeguard the interests of patients and taxpayers.

The 778 clinical trials were conducted by the 30 top European medical research universities that violate European transparency rules.

TranspariMED founder Dr Till Bruckner said: “When universities violate transparency rules, patients and taxpayers pay a steep price.

“Some universities have already posted over 90% of their trial results, showing that where there is a will, there is a way. Why are universities that break the rules still receiving public funds to run additional trials?”

The groups further warn that the true number of due trials lacking results on the public registry is likely to be far higher.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The joint report noted that 83% of all clinical trials run by the universities in Europe are verifiably in violation of EU transparency rules.

Also, the top medical universities in four countries have not made public a single clinical trial result onto the EU registry.

Additionally, the report noted that national medicines regulators across Europe fail to update registry data.

The groups warn that the true number of due trials lacking results on the public registry is expected to be far higher.